Chess Therapeutics is an oncology focused biotechnology company developing novel microtubule targeted drugs with a distinct spectrum of anti-cancer activity and pharmacologic properties compared with other microtubule targeted agents. The company’s drug candidates effectively cross the blood-brain barrier, have potential for oral delivery, and exhibit a favorable toxicity profile. They demonstrate preferential and potent activity against the aggressive brain cancer glioblastoma and cancers that carry the “cancer driving” gene mutation BRAF (melanoma, colorectal cancer, lung adenocarcinoma).
Company Details
- Founded
- -
- Address
- 15 W43rd St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- chesstherapeutics.com
- HQ
- New York, NY
Chess Therapeutics, Llc Questions
Chess Therapeutics, Llc's website is chesstherapeutics.com
Chess Therapeutics, Llc's LinkedIn profile is https://www.linkedin.com/company/chess-therapeutics-llc
Chess Therapeutics, Llc's industry is
Biotechnology Research
Chess Therapeutics, Llc's top competitors are
Metimedi Co., Ltd.,
Seal Biosciences,
Curasep,
Vivotrackai Preclinical Software,
Securitas Biosciences,
St Innovative Diagnostics Ltd.,
Mitophilix,
Epigenetic Data Sciences,
Synchrony,
St-Diagnostic.
Chess Therapeutics, Llc's categories are Biotechnology Research
Chess Therapeutics, Llc's founding year is 2016
